Ovarian Cancer
Novel Akt Inhibitor VQD-002 Shown to Reverse Cisplatin Resistance in Ovarian Cancer
Published in Law and Health Weekly, February 9th, 2008
VioQuest Pharmaceuticals (OTCBB: VQPH) announced the publication of preclinical data demonstrating that the company's lead product candidate, VQD-002 (triciribine phosphate monohydrate or TCN-P), disrupts a specific signaling pathway associated with chemoresistance and cancer cell survival in ovarian cancer. The study results, published in the current issue of the peer-reviewed publication Cancer Research, indicate that VQD-002 could play a role in reversing drug resistance in ovarian cancer for patients treated with chemotherapy in the years ahead.
Cisplatin is a chemotherapeutic agent used to treat a range of cancers including ovarian cancer. In the study, a specific...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- 40 Days for Life
Abortion Opponents in 59 Cities Prepare Focused 40-Day Campaign to Counter Impact of Roe v. Wade - Accuro Healthcare Solutions, Inc.
Accuro Healthcare Solutions, Inc. Files Registration Statement for Proposed Initial Public Offering - Aggression
New aggression study findings reported from N.E. Willard and co-authors - Aggression
Research reports from Tufts University provide new insights into aggression - American Psychological Association
Equal level of commitment and relationship satisfaction found among gay and heterosexual couples - American Veterinary Medical Association
Calling for More Veterinarians - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
